Drugs / QY101
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05429177 | Jun 2022 → Jun 2023 | — | E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06170840 | May 2023 → Feb 2024 | psoriasis | E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | QY101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05429177 ↗ |
| Route | Topical | “QY101 ointment or vehicl topical applied to skin” NCT05429177 ↗ |